$1.84
2.22% yesterday
Nasdaq, Sep 27, 10:00 pm CET
ISIN
US71715X2036
Symbol
PMCB

PharmaCyte Biotech Inc Stock price

$1.84
+0.36 24.32% 1M
-0.60 24.59% 6M
-0.32 14.81% YTD
-0.25 11.96% 1Y
-1.46 44.24% 3Y
-52.16 96.59% 5Y
-281.66 99.35% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
+0.04 2.22%
ISIN
US71715X2036
Symbol
PMCB

Key metrics

Market capitalization $13.82m
Enterprise Value $-13.49m
P/E (TTM) P/E ratio 2.67
EV/FCF (TTM) EV/FCF 4.70
P/B ratio (TTM) P/B ratio 0.29
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-5.71m
Free Cash Flow (TTM) Free Cash Flow $-2.87m
Cash position $32.64m
EPS (TTM) EPS $0.67
Short interest 0.15%
Show more

Is PharmaCyte Biotech Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Financial data from PharmaCyte Biotech Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jul '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5.31 5.31
18% 18%
-
- Research and Development Expense 0.40 0.40
2% 2%
-
-5.71 -5.71
17% 17%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.71 -5.71
17% 17%
-
Net Profit 27 27
553% 553%
-

In millions USD.

Don't miss a Thing! We will send you all news about PharmaCyte Biotech Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PharmaCyte Biotech Inc Stock News

Neutral
Business Wire
4 months ago
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”), today announced a $7 million investment in MyMD Pharmaceuticals, Inc. (Nasdaq:MYMD) (“MyMD”) a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, autoimmune and inflammatory conditions. MyMD has announced positive data for a 40-patient Phas...
Neutral
Business Wire
4 months ago
BALTIMORE--(BUSINESS WIRE)---- $MYMD--MyMD Pharmaceuticals, Inc.® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for age-related diseases, and autoimmune and inflammatory conditions, today announced that it has secured $7 million in commitments in two private placement funding rounds led by a strategic investor, Pharm...
Neutral
Business Wire
11 months ago
LAS VEGAS--(BUSINESS WIRE)--PharmaCyte Biotech, Inc. (Nasdaq: PMCB) (“PharmaCyte” or the “Company”) announces it has made a $5 million investment in Femasys, Inc. (Nasdaq:FEMY) (“Femasys”), a biomedical company focused on meeting significant unmet needs for women worldwide. Femasys offers a broad portfolio of in-office, accessible solutions, including a lead late-stage product candidate and inn...
More PharmaCyte Biotech Inc News

Company Profile

PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. It focuses on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box, which will be used as a platform for the development of treatments for inoperable pancreatic cancer and other solid cancerous tumors, and diabetes. The company was founded on October 28, 1996 and is headquartered in Laguna Hills, CA.

Head office United States
CEO Joshua Silverman
Employees 2
Founded 1996
Website pharmacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today